Skip to main content
xMedica

NCT07321899ClinicalTrials.gov

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Interventional1,186 participants sought20 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-07; recorded start 2026-09-11
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Cardiovascular)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 4 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,186 participants (target), run at 20 sites.

How this score is built
  • Enrolment31/40

    1,186 participants (target)

  • Site count7/25

    4 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 179 months

  • Sponsor scale4/10

    Medtronic Cardiovascular has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.

Conditions

  • Severe Tricuspid Regurgitation

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Age ≥18 years at the time of consent. * Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT). * Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR. Exclusion Criteria: * Any tricuspid device currently in place. * Anatomic contraindications. * Need for emergent or urgent surgery. * Left ventricular ejection fraction \<25%.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhaseNot applicable
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingSINGLE (1)
Enrolment1,186 participants sought

Sponsor and collaborators

  • Medtronic Cardiovascular Sponsor

Arms and interventions

  • Medtronic Intrepid™ TTVREXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation.

  • Edwards EVOQUE TTVRACTIVE_COMPARATOR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation.

  • Single Arm RegistryEXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization.

Interventions

  • Device Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

  • Device Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

Outcome measures

  1. Primary outcome

    Rate of Major Adverse Events (MAE)

    Time frame 30-days post-procedure

  2. Primary outcome

    Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention

    Time frame 1-year post-procedure

  3. Secondary outcome

    Tricuspid regurgitation (TR) grade reduction

    Total number of patients with at least one grade TR reduction

    Time frame 6 months post-procedure

  4. Secondary outcome

    Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

    KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life

    Time frame 6 months post-procedure

  5. Secondary outcome

    All-cause mortality

    Time frame 12 months post-procedure

  6. Secondary outcome

    Heart failure hospitalization

    Time frame 12 months post-procedure

  7. Secondary outcome

    New onset conduction disturbance (NOCD)

    Time frame 30 days post-procedure

  8. Secondary outcome

    Total procedure time

    Time frame Procedure

  9. Secondary outcome

    Right ventricle (RV) dysfunction

    Time frame 12 months post-procedure

Dates

Dates
Start dateSeptember 11, 2026 (actual)
Primary completionSeptember 1, 2031 (estimated)
CompletionApril 1, 2041 (estimated)
First postedJanuary 7, 2026 (actual)
Last updatedNovember 12, 2026
Results postedNot stated in the registry record
Status last verifiedNovember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

20 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Emory University Hospital MidtownAtlantaGeorgiaRecruiting
University of Alabama at Birmingham (UAB) HospitalBirminghamAlabamaRecruiting
Buffalo General Medical CenterBuffaloNew YorkRecruiting
Northwestern Memorial HospitalChicagoIllinoisRecruiting
The Christ HospitalCincinnatiOhioRecruiting
Cleveland Clinic FoundationClevelandOhioRecruiting
Hartford HospitalHartfordConnecticutRecruiting
Cedars Sinai Medical CenterLos AngelesCaliforniaRecruiting
Northwell Health North Shore University HospitalManhassetNew YorkRecruiting
Abbott Northwestern HospitalMinneapolisMinnesotaRecruiting
Morristown Medical CenterMorristownNew JerseyRecruiting
Yale New Haven HospitalNew HavenConnecticutRecruiting
Montefiore Medical CenterNew YorkNew YorkRecruiting
NYU Langone Medical CenterNew YorkNew YorkRecruiting
The Valley HospitalParamusNew JerseyRecruiting
Abrazo Arizona Heart HospitalPhoenixArizonaRecruiting
Kaiser Permanente San Francisco Medical CenterSan FranciscoCaliforniaRecruiting
Los Robles Hospital & Medical CenterThousand OaksCaliforniaRecruiting
Ascension Via Christi Saint FrancisWichitaKansasRecruiting
Lankenau Institute for Medical ResearchWynnewoodPennsylvaniaRecruiting

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 12, 2026

    Site added

    7 sites added (20 total)

    1320

  2. September 25, 2026

    Site added

    9 sites added (13 total)

    413

  3. July 28, 2026

    Status changed

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. July 28, 2026

    Recruitment opened

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. July 28, 2026

    Site added

    4 sites added (4 total)

    04